143 related articles for article (PubMed ID: 2113797)
1. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
Heim-Duthoy K; Peltier G; Awni W
Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics and tolerance of fleroxacin in healthy male volunteers.
Nakashima M; Kanamaru M; Uematsu T; Takiguchi A; Mizuno A; Itaya T; Kawahara F; Ooie T; Saito S; Uchida H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():133-44. PubMed ID: 3144532
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
Panneton AC; Bergeron MG; LeBel M
Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
[TBL] [Abstract][Full Text] [Related]
5. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
6. Metabolism of fleroxacin in man.
Sörgel F; Seelmann R; Naber K; Metz R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
[TBL] [Abstract][Full Text] [Related]
7. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in elderly patients.
Taburet AM; Devillers A; Thomare P; Fillastre JP; Veyssier P; Singlas E
Clin Pharmacokinet; 1990 Jul; 19(1):80-8. PubMed ID: 2116257
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
9. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of cefonicid in patients with skin and skin structure infections.
Heim-Duthoy KL; Peltier GL; Guay DR; Matzke GR
Antimicrob Agents Chemother; 1988 Apr; 32(4):485-7. PubMed ID: 3377460
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
12. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
[TBL] [Abstract][Full Text] [Related]
13. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
Lubowski TJ; Nightingale C; Sweeney K; Quintiliani R; Zhi J
Antimicrob Agents Chemother; 1992 Mar; 36(3):651-5. PubMed ID: 1622179
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.
Hirata CA; Guay DR; Awni WM; Stein DJ; Peterson PK
Antimicrob Agents Chemother; 1989 Nov; 33(11):1927-31. PubMed ID: 2610503
[TBL] [Abstract][Full Text] [Related]
15. Influence of rifampin on fleroxacin pharmacokinetics.
Schrenzel J; Dayer P; Leemann T; Weidekamm E; Portmann R; Lew DP
Antimicrob Agents Chemother; 1993 Oct; 37(10):2132-8. PubMed ID: 8257135
[TBL] [Abstract][Full Text] [Related]
16. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
[TBL] [Abstract][Full Text] [Related]
17. Disposition of fleroxacin, a new trifluoroquinolone, and its metabolites. Pharmacokinetics in renal failure and influence of haemodialysis.
Singlas E; Leroy A; Sultan E; Godin M; Moulin B; Taburet AM; Dhib M; Fillastre JP
Clin Pharmacokinet; 1990 Jul; 19(1):67-79. PubMed ID: 2116256
[TBL] [Abstract][Full Text] [Related]
18. A new trifluorinated quinolone: Ro 23-6240 (AM 833).
Weidekamm E; Stöckel K; Dell D
Drugs Exp Clin Res; 1987; 13(2):85-90. PubMed ID: 3107959
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
[TBL] [Abstract][Full Text] [Related]
20. First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.
Jiao Y; Kim TH; Tao X; Kinzig M; Landersdorfer CB; Drescher SK; Sutaria DS; Moya B; Holzgrabe U; Sörgel F; Bulitta JB
Eur J Pharm Sci; 2018 Oct; 123():416-428. PubMed ID: 30076955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
